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AbsTrACT
Amblyopia therapy options have traditionally been 
limited to penalisation of the non-amblyopic eye 
with either patching or pharmaceutical penalisation. 
Solid evidence, mostly from the Pediatric Eye Disease 
Investigator Group, has validated both number of hours 
a day of patching and days per week of atropine use. The 
use of glasses alone has also been established as a good 
first-line therapy for both anisometropic and strabismic 
amblyopia. Unfortunately, visual acuity equalisation 
or even improvement is not always attainable with 
these methods. Additionally, non-compliance with 
prescribed therapies contributes to treatment failures, 
with data supporting difficulty adhering to full treatment 
sessions. Interest in alternative therapies for amblyopia 
treatment has long been a topic of interest among 
researchers and clinicians alike. Incorporating new 
technology with an understanding of the biological 
basis of amblyopia has led to enthusiasm for binocular 
treatment of amblyopia. Early work on perceptual 
learning as well as more recent enthusiasm for iPad-
based dichoptic training have each generated interesting 
and promising data for vision improvement in amblyopes. 
Use of pharmaceutical augmentation of traditional 
therapies has also been investigated. Several different 
drugs with unique mechanisms of action are thought 
to be able to neurosensitise the brain and enhance 
responsiveness to amblyopia therapy. No new treatment 
has emerged from currently available evidence as 
superior to the traditional therapies in common practice 
today. But ongoing investigation into the use of both 
new technology and the understanding of the neural 
basis of amblyopia promises alternate or perhaps better 
cures in the future.
InTroduCTIon
Amblyopia therapy has benefited significantly from 
the investigations of the Paediatric Eye Disease 
Investigator Group (PEDIG). There have been 18 
completed Amblyopia Treatment Studies (ATS) as 
of publication of this review. In these well-designed, 
predominantly randomised controlled trials, there 
have been numerous notable conclusions that 
continue to shape and dictate how to care for chil-
dren with amblyopia. Early studies provided solid 
epidemiological data on patients with amblyopia.1–3 
Through the early studies, the equivalent effi-
cacy of patching versus atropine penalisation was 
established.4–6 Concern that cessation of treatment 
would lead to a relapse in amblyopia was widely 
touted, but 15-year follow-up data confirmed that 
the amblyopia treatment effect persisted.7
Traditional amblyopia treatment strategies have 
documented improvement with spectacle correction 
when indicated, followed by patching or atropine 
penalisation of the non-amblyopic ('fellow') eye. 
While the majority of children show improvement 
with these approaches, not all children respond to 
traditional therapies. Even responders often have 
residual amblyopia. Fifty-four per cent of children 
treated at age <3–7 years still demonstrate some 
amblyopia at age 10.4 Older children fair even 
worse; 74% of children aged 7–12 years treated 
with patching, and 80% treated with atropine have 
some degree of residual amblyopia on long-term 
follow-up.5 In the teenage cohort, outcomes are 
even less effective with only one-quarter to one-half 
of children responding to combined treatment of 
spectacles and patching depending on whether they 
had previous treatment or were treatment naïve 
(respectively).6
Non-compliance contributes to treatment fail-
ures, with data supporting less than perfect adher-
ence to prescribed regimens.8 However, data from 
use of an occlusion dose monitor confirmed that 
some children demonstrate excellent compliance, 
yet still fail to improve.9 10 This suggests an oppor-
tunity for novel strategies to target non-compliant 
patients and non-responders. In this review, we will 
explore the binocular therapies as an alternative to 
traditional amblyopia treatments, as well as phar-
macologic adjuncts to standard regimens.
bInoCulAr TherApIes
background and rationale
The depth of amblyopia has been positively 
correlated to the degree of binocular imbalance.11 
Affected individuals show impaired stereoacuity 
and abnormal binocular summation.12 Yet evidence 
suggests that binocular cortical communication 
persists in subjects with amblyopia.13 14 These find-
ings are the basis for the hypothesis that activation 
of these persistent binocular neural circuits might be 
exploited to 'awaken' an amblyopic eye. Binocular 
therapies designed to improve amblyopia through 
binocular stimulation are largely broken down into 
perceptual learning and dichoptic training.
perceptual learning
Perceptual learning was defined in 1963 by Eleanor 
Gibson as an evolution in the discernment of a stim-
ulus array after repetitive exposure or practice with 
this array.15 This work is the psychophysical valida-
tion of the old adage 'Practice makes perfect'. Perfor-
mance on simple visual tasks has been long known 
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Figure 1  Dichoptic stimuli as presented to the patient with amblyopia. The stimuli are adjusted so that the dominant eye (DE), in this case the left 
eye (LE), has less contrast and is therefore more difficult to discriminate than the non-dominant eye (NDE). When the images are superimposed, the 
subject perceives a single percept with summation of elements presented to each eye separately. Over time, the contrast can be adjusted as the non-
dominant eye improves with training (reproduced from Ding and Levi, figure 1A) .62 RE, right eye.
of perceptual learning to various visual tasks has reportedly 
resulted in improvement in several measures, including orien-
tation discrimination, stereoacuity and contrast sensitivity.16 A 
number of visual tasks have been explored as a means to apply 
perceptual learning, including vernier acuity, Gabor detection, 
positional discrimination, letter identification in noise, position 
discrimination in noise and contrast detection.17
Studies by Polat et al suggest that perceptual learning in 
adult amblyopes can augment visual function. Improved pretest 
to post-test performance and gains in visual acuity (VA) were 
reported when subjects participated in a learnt trial of Gabor 
signals in a series of 77 adult amblyopes.18 The criticism of this 
approach is that gains on test outcome measures in the ambly-
opic eye do not transfer to novel situations—improvement 
is only seen for the task practised.19 Advocates of perceptual 
learning note that the specific nature of the stimuli chosen for 
training tasks contributes to the capacity for generalisability of 
the trained discrimination.20 Others cite the targeted reduction 
in the detrimental effect of crowding (a reduction in VA when 
viewing a line of linear letters more severe than when viewing 
letters individually).21 The neural basis for this is postulated to 
result from a reduction in lateral inhibition within the brain with 
training.22
Small studies of juvenile amblyopes have demonstrated 
improvements. Seven participants with prior occlusion therapy 
had improved visual performance following completion of a 
positional discrimination task.23 A second pilot study of five 
amblyopic children who underwent 40 hours of perceptual 
learning demonstrated improved scores on Snellen acuity and 
contrast sensitivity. There was no follow-up following comple-
tion of the treatment regimen.24 In their comprehensive review 
of perceptual learning, Levi and Li reported on the relative effec-
tiveness of the various types of tasks in both performance of the 
trained task and Snellen acuity. Five of the 12 studies reviewed 
showed improvement in post-test results, of which 4 employed 
practising contrast detection. The fifth study examined extended 
positional acuity learning in children.17  25
Drawbacks to treatment
Perceptual learning has yet to gain widespread support. Most 
of the aforementioned studies contained very small numbers 
of participants, limiting generalisability to populations at large. 
Perceptual learning effects have been demonstrated to last hours 
to months without continued practice,26 but long-term follow-up 
is lacking. Additionally, implementation of a successful clinical 
programme of treatment would require the ability to perform 
training at home while the aforementioned studies required 
perceptual learning tasks to be in a laboratory setting.
dichoptic training
Unlike perceptual learning, where a single visual percept is 
administered to both eyes simultaneously or under monocular 
viewing conditions, dichoptic treatment presents independent 
stimuli to each eye (figure 1). The therapy derives its effect from 
unlocking binocular visual function. The treatment effect then 
follows from introducing a task that requires the integration of 
the two stimuli under binocular viewing conditions. The para-
digm is customised to overcome the patient’s suppression of the 
amblyopic eye. To do so, the image shown to the amblyopic eye 
must be of higher contrast than that shown to the fellow eye.14 
27 As the patient’s developing binocular function improves, the 
contrast difference between the two eyes is reduced, potentially 
to a point where no difference is required. VA gains follow 
improvements in binocularity and contrast sensitivity, presum-
ably due to reduced suppression.24
Early reports of dichoptic training used this concept in a clin-
ic-based setting with the adult amblyopes.28–30 They demon-
strated both proof-of-concept as well as the potential for 
amblyopia improvement outside of the critical period. Hess et al 
showed statistically significant improvements in amblyopic eye 
visual and stereoacuity in nine adults (four of whom had prior 
patching treatment).28
In order to move the therapy from a clinic-based, observed 
task to mobile, home-based use, it was necessary to adapt the 
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overlay (a textured screen overlay that produces images with 
a perception of depth, eg, holograms) allowed for viewing the 
dichoptic stimuli, but required stable head positioning. While 
studies suggest that such method is successful, it is a challenge 
to use.31 A shift away from the lenticular design and transition 
to anaglyphic (red-green dichoptic) images with accompanying 
red-green glasses overcame this limitation and permitted utilisa-
tion of this form of therapy by young children and in unsuper-
vised patients.29 32
binocular ipad therapy
Interest in dichoptic treatment progressed with the migration of 
the Hess Falling Blocks game onto an iPad. Birch and colleagues 
conducted a small study of children aged 4–12 playing this 
dichoptic iPad game using red-green anaglyphic glasses for 4 
hours/week over 4 weeks and saw improvement in amblyopic 
eye logMAR acuity (0.47–0.39, p<0.001).33 A subsequent study 
looking at younger children confirmed previous work demon-
strating improved amblyopic-eye acuity as well as a dose-re-
sponse effect.32 Those children completing 8 total hours of game 
play during the 4-week study had significantly greater improve-
ment than those playing 0–4 hours. The results of these early 
studies suggested promise for dichoptic training in the treatment 
of amblyopia.
In 2015, PEDIG conducted the first large-scale, multisite 
randomised controlled trial comparing the effectiveness of 
1 hour/day, 7 days/week binocular game play to 2 hours/day 
patching in children<13 as a non-inferiority study. There was 
a parallel superiority study examining the same regimen in chil-
dren aged 13 to <17 years. Results of the non-inferiority study 
in the younger cohort demonstrated improvement in both the 
1 hour/day iPad game play as well as the 2 hours/day patching 
groups with no statistically significant difference between the 
groups at 16 weeks. There were no side effects of treatment, 
specifically diplopia, reduction in fellow eye VA or new tropia. A 
disappointing finding of the study was the poor overall compli-
ance in the binocular game group.34 The 13 to <17 years age 
group cohort results were similar; amblyopic eye VA was not 
better with iPad play, and was possibly worse. Compliance 
was similarly poor, with 13% completing >75% of prescribed 
treatment.35
Similar work by Gao et al compared 1 hour of home-based, 
dichoptic falling-blocks video game play to a placebo game.36 
They recruited participants age 7 years and up, including adults 
18 years and older. Results failed to show a meaningful differ-
ence in amblyopic eye 6-week VA, the primary outcome of 
interest. They found no significant age effect, type of amblyopia 
or impact of prior occlusion treatment.
Drawbacks to treatment
While initially heralded as superior to patching due to theo-
rised improved compliance, the results of the first randomised 
controlled trial were underwhelming. Less than one-quarter of 
children in the PEDIG study completed 75% of prescribed treat-
ment time.34 Thus, ironically, non-compliance has dampened 
enthusiasm for binocular amblyopia treatment over traditional 
therapies. The theorised rationale for the high rate of non-com-
pliance is that the Falling Blocks game was not stimulating 
enough to encourage a full hour of play on multiple days per 
week. The author’s own experience included patient reports 
of preference for patching due to the wider range of activities 
that could be performed with a patch over the repetitive play 
on the iPad game. Similarly, poor compliance and participant 
dropout was seen in weeks 4–6 in the study by Gao et al.36 This 
led the authors to suggest the need for more engaging games 
with potential reward reinforcement as the next iteration of 
binocular iPad play. Use of a more stimulating Dig Rush game 
has shown promise37 and recruitment is currently underway for 
a randomised controlled trial comparing play with glasses with 
glasses alone (NCT02983552).
Alternative technologies
While iPad-based platforms for binocular treatment of amblyopia 
have the most research into their use incorporating a variety of 
study designs and age groups, alternative technological presen-
tations of binocular therapy have been created. Passive viewing 
of dichoptic movies has demonstrated success in a paediatric 
cohort both with compliance and vision outcomes. Study limita-
tions included short, 2-week follow-up and lack of randomised 
design.38 Head-mounted virtual reality displays have also shown 
preliminary evidence to suggest improvement in both VA and 
stereoacuity in adult patients39 as has video game play.40 41 This 
latter study by Vedamurthy et al also demonstrated retention of 
VA and stereoacuity after a 2-month time period.41 Continuously 
evolving technology will likely yield additional means to deliver 
dichoptic stimuli in engaging, interactive platforms; hopefully, 
with the added benefit of effectiveness and patient compliance.
Interactive binocular treatment (I-BiT) system was developed 
to treat amblyopia using dichoptic stimuli presented via virtual 
reality game play or movie watching.42 The special software 
selectively stimulates the amblyopic eye without compromising 
vision in the fellow eye. Initial pilot studies showed promise 
improving the VA of paediatric and adult patients with ambly-
opia.43–45 Use of shutter glasses has also been paired with this 
technology, where the glasses lighten and darken in synchrony 
with the monitor, allowing an enriched image to be presented to 
the amblyopic eye only.41 46 In one study, all subjects used shutter 
glasses to present dichoptic stimuli but were randomised to one 
of three arms: active I-BiT game play, passive I-BiT DVD use or 
non-I-BiT game play. There was improvement in all groups in VA, 
with no meaningful difference found between the groups. Inter-
estingly, the game platform that included an interactive shooter 
game and DVD, had >90% participant-reported satisfaction 
with treatments.46 This lends further support to the notion of 
patient engagement in treatment success or compliance.
The drug TherApIes
background and rationale
Amblyopia is considered to be most receptive to treatments 
initiated within the 'critical period', during which cortical brain 
plasticity allows for reversal of some or all of the visual loss in 
the non-dominant eye. Results of the ATS have shown that the 
critical period is protracted with visual improvement possible up 
to age 17 years. However, the response to treatment is greatest 
under age 7 years, with waning benefit with increasing age. 
Furthermore, treatment during the teen years disproportionately 
benefits those with no prior history of treatment.47 The oppor-
tunity to neurosensitise a brain to allow for improvement with 
patching or atropine in children for whom conventional treat-
ments have failed or after the critical period has ended is desir-
able. Pharmaceutical agents may offer that ability and a select 
few have reached human studies.
pharmacologic options: levodopa-carbidopa
A theory has been proposed that increasing levels of dopa-
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investigators have reported that levels of retinal dopamine 
are decreased in deprivation amblyopia.48 The first report 
of dopamine augmentation came in 1990 when Gottlob and 
Stangler-Zuschrott examined the effect of levodopa on adult 
amblyopia.49 Levodopa is the immediate metabolic precursor of 
dopamine and is Food and Drug Administration approved for 
use in other neurological disorders.
There have been several clinical trials that have evaluated 
the use of levodopa across a range of patients. PEDIG investi-
gators organised a randomised trial of levodopa for the treat-
ment of amblyopia in an older cohort of patients (children 
aged 7–12 years). When prescribed daily levodopa with carbi-
dopa in addition to continued 2 hours/day of patching, no clin-
ically significant or meaningful improvement in VA was seen. 
Reassuringly, no serious adverse events were reported.50 In a 
different prospective trial with a larger cohort of patients, chil-
dren who had previously received spectacles but were otherwise 
treatment-naïve were prescribed full-time patching and then 
randomised to levodopa or placebo. The authors reported statis-
tically significant visual gains sustained at 1 year of follow-up 
for children in the levodopa group. In this study, the levodopa 
dosage was three times higher than in the PEDIG study.51
pharmacologic options: citicoline
Citicoline is a complex biomolecule involved in cellular metab-
olism. Its structure confers both cholinergic and neuroprotec-
tive properties.52 Due to its role in phospholipid metabolism, 
citicoline has been theorised to protect the anatomic and struc-
tural integrity of cell membranes, thereby preventing nerve cell 
damage. This has led to its use for the recovery from traumatic, 
ischaemic and degenerative insults.53 It was initially trialled in 
ophthalmic care for the treatment of glaucoma.54
Initial work in adult patients demonstrated improvement 
in VA with citicoline augmentation of patching that was not 
sustained following cessation of the medication.55 Early studies 
in amblyopic children were promising, showing treatment effect 
with citicoline both alone and in addition to patching.56 57  
A study of treatment-naïve participants randomised to added 
citicoline after a run-in patching phase showed a significant 
treatment effect at 90 days for the citicoline-augmented group.58 
However, failure to demonstrate improvement in the control 
group (2 hours a day of patching) was unexpected and therefore 
results from this study should be cautiously interpreted.
Research into the use of citicoline is arguably behind that 
of levodopa. Well-designed randomised controlled trials and 
appropriately selected treatment groups need to be initiated. 
At the time of this review, all the studies of citicoline failed to 
include follow-up periods beyond 3–6 months.
Drawbacks to medical therapy
Pharmaceutical augmentation of amblyopia therapy appears to 
be well tolerated. A liquid suspension of levodopa is available 
to facilitate use in a young patient population, although has a 
reportedly unpleasant bitter taste.59 60 Side effects of levodopa 
therapy are reassuringly mild, with children describing mild 
nausea, vomiting and headache31 32 and not severe enough to 
necessitate cessation of treatment. The addition of carbidopa to 
the prescribed formulation reduces these gastrointestinal side 
effects by inhibiting peripheral conversion of levodopa to dopa-
mine. Because carbidopa cannot cross the blood-brain barrier, 
it only prevents levodopa conversion peripherally and allows 
more central activity of levodopa. One worrisome result from 
the PEDIG study was regression of treatment effect with drug 
cessation.31 Therefore, randomised controlled trials with ample 
follow-up still remain necessary. Side effects of citicoline were 
negligible in all studies. In early use, intramuscular injection 
was the only means of administration; however, there is now an 
oral formation.61 Medical therapy, in isolation or in addition to 
conventional therapy, is still in its infancy and potential agents 
are in the research and development stages.
summAry/ConClusIons
The past 15 years have been replete with well-designed, prospec-
tive controlled clinical trials to demonstrate both the efficacy and 
limitations of traditional amblyopia therapies. Novel approaches 
to this problem have met with mixed success. Perceptual learning 
and medical intervention have shown promise, but lack well-de-
signed studies to suggest sustained effect outside the treatment 
period. Dichoptic training has extensive research suggesting 
effectiveness, but the most recent randomised trial failed to 
demonstrate non-inferiority over standard treatments. Future 
investigation will likely continue to modify and adapt these 
novel approaches to generative creative, engaging amblyopia 
therapies that may benefit children and adults, alike.
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